stocks logo

SLDB

Solid Biosciences Inc
$
6.230
-0.14(-2.198%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.350
Open
6.320
VWAP
5.98
Vol
2.17M
Mkt Cap
482.92M
Low
5.740
Amount
12.95M
EV/EBITDA(TTM)
--
Total Shares
38.38M
EV
189.50M
EV/OCF(TTM)
--
P/S(TTM)
--
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.492
-19.34%
--
--
-0.502
-36.46%
--
--
-0.513
-48.71%
Estimates Revision
The market is revising No Change the revenue expectations for Solid Biosciences Inc. (SLDB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 75.00%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.11%
In Past 3 Month
Stock Price
Go Up
up Image
+75.00%
In Past 3 Month
12 Analyst Rating
up Image
156.82% Upside
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 16.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
up Image
156.82% Upside
Current: 6.230
sliders
Low
10.00
Averages
16.00
High
20.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
2025-06-18
Reason
H.C. Wainwright reiterates a Buy rating on Solid Biosciences (SLDB) after Sarepta (SRPT) disclosed a second patient death due to acute liver failure following treatment with Elevidys. The news underscores the favorable safety profile of Solid's SGT-003, the analyst tells investors in a research note. The firm believes SGT-003 has the most favorable safety profile among the leading Duchenne muscular dystrophy gene therapies either in clinic or in the market. Wainwright expects a meaningful share of ambulatory patients to transition from Elevidys to SGT-003.
Barclays
Overweight
downgrade
$15 -> $10
2025-05-16
Reason
Barclays lowered the firm's price target on Solid Biosciences to $10 from $15 and keeps an Overweight rating on the shares. The company's Q1 report was largely incremental, with continued pipeline progress, the analyst tells investors in a research note.
Piper Sandler
Piper Sandler
Overweight
downgrade
$20 -> $17
2025-05-16
Reason
Piper Sandler lowered the firm's price target on Solid Biosciences to $17 from $20 and keeps an Overweight rating on the shares following quarterly results and update. Dosing is ongoing in the Phase 1/2 INSPIRE DUCHENNE trial, with next data update in about 10-12 patients expected in Q4 2025 after planned FDA meeting to discuss the accelerated approval pathway. In parallel, Solid Biosciences is gearing up for the initiation of its first-in-human Phase 1b Friedreich's Ataxia study with SGT-212 in Q4 2025, which will include both ambulatory and non-ambulatory patients, Piper adds.
Wedbush
Outperform
downgrade
$18 -> $17
2025-05-16
Reason
Wedbush lowered the firm's price target on Solid Biosciences to $17 from $18 on higher share count, while keeping an Outperform rating on the shares. The firm says the most important in the company's update was that all key development timelines remain on track. Solid Biosciences continues to anticipate making an FDA meeting request this summer to discuss SGT-003 accelerated approval pathway options and plans to complete dosing in by 20 subjects by Q4 2025. All in, Wedbush remains impressed by the early INSPIRE data and sees limited credit being assigned at present levels.
JP Morgan
Anupam Rama
Buy
Maintains
$12 → $11
2025-03-13
Reason
JPMorgan lowered the firm's price target on Solid Biosciences to $11 from $12 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.
HC Wainwright & Co.
Arthur He
Strong Buy
Maintains
$16 → $20
2025-03-10
Reason

Valuation Metrics

The current forward P/E ratio for Solid Biosciences Inc (SLDB.O) is -3.12, compared to its 5-year average forward P/E of -2.78. For a more detailed relative valuation and DCF analysis to assess Solid Biosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.78
Current PE
-3.12
Overvalued PE
-0.63
Undervalued PE
-4.92

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.71
Current EV/EBITDA
-1.28
Overvalued EV/EBITDA
0.62
Undervalued EV/EBITDA
-2.04

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
29.33
Current PS
0.00
Overvalued PS
76.99
Undervalued PS
-18.34

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+49.10%
-40.05M
Operating Profit
FY2025Q1
YoY :
+61.63%
-39.28M
Net Income after Tax
FY2025Q1
YoY :
-7.81%
-0.59
EPS - Diluted
FY2025Q1
YoY :
+26.18%
-31.98M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
152.8K
USD
7
0-12
Months
19.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
3
24.2M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 965.6% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.1M
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
16.2M
Volume
Months
6-9
3
1.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

SLDB News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
08:43:46
Vor Bio appoints Cumbo, Detheux to board of directors
select
2025-07-08 (ET)
2025-07-08
16:21:16
Solid Biosciences announces FDA, Health Canada approval for SGT-501 IND
select
2025-06-03 (ET)
2025-06-03
08:05:24
Solid Biosciences reports inducement grants under Nasdaq listing rule
select
Sign Up For More Events

News

4.0
07-14TipRanks
3 Best Stocks to Buy Now, 7/14/2025, According to Top Analysts
7.0
07-10PRnewswire
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm
4.0
07-09Yahoo Finance
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT
Sign Up For More News

FAQ

arrow icon

What is Solid Biosciences Inc (SLDB) stock price today?

The current price of SLDB is 6.23 USD — it has decreased -2.2 % in the last trading day.

arrow icon

What is Solid Biosciences Inc (SLDB)'s business?

arrow icon

What is the price predicton of SLDB Stock?

arrow icon

What is Solid Biosciences Inc (SLDB)'s revenue for the last quarter?

arrow icon

What is Solid Biosciences Inc (SLDB)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Solid Biosciences Inc (SLDB)'s fundamentals?

arrow icon

How many employees does Solid Biosciences Inc (SLDB). have?

arrow icon

What is Solid Biosciences Inc (SLDB) market cap?